Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 5/2004

01-05-2004 | Meeting Report

British Society for Immunology annual congress, Harrogate, UK, 2–5 December 2003

Author: Graham Pawelec

Published in: Cancer Immunology, Immunotherapy | Issue 5/2004

Login to get access

Excerpt

Cancer immunology and immunotherapy has now become such an established part of mainstream immunology that it is hard to remember when tumour immunologists were considered to be working in an area regarded as not quite ‘proper’. This was amply illustrated at this year’s annual congress of the British Society for Immunology (BSI) in Harrogate, UK, 2–5 December 2003. Although not specifically focused on tumour immunology, many excellent presentations dealt with subjects central to this topic. …
Metadata
Title
British Society for Immunology annual congress, Harrogate, UK, 2–5 December 2003
Author
Graham Pawelec
Publication date
01-05-2004
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 5/2004
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-003-0497-1

Other articles of this Issue 5/2004

Cancer Immunology, Immunotherapy 5/2004 Go to the issue

Review

Trials and tribulations of immunotherapy as a treatment option for patients with squamous cell carcinoma of the head and neck

Original Article

Effect of albumin fusion on the biodistribution of interleukin-2

Original Article

Polyclonal T-cell activation protocol stimulates preferential expansion of EBV-specific T-cell clones in vitro

Original Article

In vivo priming of natural killer T cells by dendritic cells pulsed with hepatoma-derived acid-eluted substances

Original Article

Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3

Original Article

Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits